SOLO COVID-19 : In vivo & in vitro solutions to evaluate your prophylactic and therapeutic solutions
SOLO COVID-19 is the product of Oncodesign’s pharmacological expertise combined with our agility and societal commitment. This offer was swiftly deployed in 2020, allowing – with rigor and safety – the implementation of specific in vitro and in vivo pharmacology studies to evaluate new prophylactic, therapeutic or vaccinal approaches to combat COVID-19.
Innovative in vitro and in vivo models to evaluate the potential of your products
Evaluate your treatment strategies to combat COVID-19 and its complications
In collaboration with our partners IDMIT and SEPIA of the CEA, SOLO Covid-19 offers the ability to evaluate the efficacy of new therapeutic options as well as repositioning of pre-existing options.
This offer is based on the use of an integrated panel of biochemical and cellular assays, including animal models, infected with SARS-CoV-2 or modeling inflammatory pulmonary complications.
Biochemical assays for Spike S protein binding, SARS-CoV-2 viral protease activities, human ACE2 protein binding and human TMPRSS2 protease activity.
Infection tests of human and simian cells by the original SARS-CoV-2 variant and its variants (alpha, beta, gamma and delta) to assess the potential of compounds on viral load, cytopathogenic effect, immune modulation and air-liquid interface.
Models of SARS-CoV-2 infection of transgenic mice, or non-lethal native infection of hamsters and non-human primates, using multiple analyses including imaging.
Severe inflammatory model of pulmonary fibrosis in mice, to assess the proof of concept of therapeutic solutions oriented in the management and treatment of post-acute respiratory distress syndrome.